Fate Therapeutics (FATE)

$1.84 -0.05 (-2.65%)
Market Cap 220.30M
Revenue (ttm) 6.65M
Net Income (ttm) -136.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,049.92%
Debt to Equity Ratio 0.00
Volume 2,877,700
Avg Vol 2,249,444
Day's Range N/A - N/A
Shares Out 116.56M
Stochastic %K 29%
Beta 2.13
Analysts Sell
Price Target $5.17

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 875 1800
Address:
12278 Scripps Summit Drive, San Diego, United States
WestEgg
WestEgg May. 21 at 3:03 PM
$FATE Scenario Approximate Enterprise Value Technology tuck-in $1B–$2B Strong autoimmune validation $3B–$5B Breakthrough outpatient CAR-T platform $5B–$10B+
0 · Reply
WestEgg
WestEgg May. 21 at 2:34 PM
$FATE Most Likely Order $1B-$7B 1. Bristol Myers Squibb 2. Gilead/Kite 3. AstraZeneca 4. Johnson & Johnson 5. Novartis 6. Regeneron 7. Roche The single biggest determinant now is whether FT819’s autoimmune data continues improving through 2026.
0 · Reply
Rocketman808
Rocketman808 May. 21 at 2:18 PM
$FATE 2000 more shares at 1.80 was all i could do but glad i acted quick!! lets hit 2s again!!
0 · Reply
student56
student56 May. 21 at 2:14 PM
$FATE hold
0 · Reply
Icansee
Icansee May. 21 at 1:45 PM
$FATE
0 · Reply
Rocketman808
Rocketman808 May. 21 at 1:39 PM
$FATE nice place to add waiting for payday lol
0 · Reply
Doozio
Doozio May. 20 at 11:57 PM
The $FATE of da YO vs turnaround Tuesday $HALO ONTO 🐒🍌🧠⏰♾️
0 · Reply
GoosingIt
GoosingIt May. 20 at 10:18 PM
$FATE Will be interested to see if a positive FT836 abstract moves this tomorrow.
0 · Reply
buymoremakemore
buymoremakemore May. 20 at 3:36 PM
$FATE I added 32k shares here. It was between this and IPSC. Pipeline and cash look good here. Could be takeout target
0 · Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates May. 20 at 2:18 PM
$FATE "The firm also expects strong responses and durability comparable to autologous CAR-T therapy" - Excerpt from the following article: https://www.investing.com/news/analyst-ratings/jefferies-initiates-fate-therapeutics-stock-with-buy-rating-on-autoimmune-potential-93CH-4699446
0 · Reply
Latest News on FATE
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

May 21, 2026, 8:30 AM EDT - 3 hours ago

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

Fate Therapeutics assumed with a Buy at Jefferies

2026-05-19T19:15:09.000Z - 1 day ago

Fate Therapeutics assumed with a Buy at Jefferies

Fate Therapeutics reports Q1 EPS (26c), consensus (28c)

2026-05-13T15:28:57.000Z - 8 days ago

Fate Therapeutics reports Q1 EPS (26c), consensus (28c)

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

May 13, 2026, 8:30 AM EDT - 8 days ago

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Fate Therapeutics Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 8 days ago

Fate Therapeutics Earnings release: Q1 2026

Fate Therapeutics Quarterly report: Q1 2026

May 13, 2026, 8:30 AM EDT - 8 days ago

Fate Therapeutics Quarterly report: Q1 2026

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

May 11, 2026, 8:30 AM EDT - 10 days ago

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

May 5, 2026, 8:30 AM EDT - 16 days ago

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

May 4, 2026, 9:00 AM EDT - 17 days ago

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright

2026-05-04T10:17:06.000Z - 17 days ago

Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2026, 4:05 PM EDT - 19 days ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

Apr 30, 2026, 9:00 AM EDT - 21 days ago

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

SLE

Fate Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 27 days ago

Fate Therapeutics Proxy statement: Proxy filing

Fate Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 27 days ago

Fate Therapeutics Proxy statement: Proxy filing

Fate Therapeutics announces data presentation of FT839

2026-04-16T13:53:30.000Z - 5 weeks ago

Fate Therapeutics announces data presentation of FT839

Fate Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 3:45 PM EDT - 5 weeks ago

Fate Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 9:20 AM EDT - 2 months ago

Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2026, 4:05 PM EST - 2 months ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

Mar 3, 2026, 4:05 PM EST - 2 months ago

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

Fate Therapeutics reports Q4 EPS (77c), consensus (27c)

2026-02-26T14:07:37.000Z - 3 months ago

Fate Therapeutics reports Q4 EPS (77c), consensus (27c)

Fate Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 3 months ago

Fate Therapeutics Earnings release: Q4 2025

Fate Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 3 months ago

Fate Therapeutics Annual report: Q4 2025

Fate Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 3 months ago

Fate Therapeutics Annual report: Q4 2025

Fate Therapeutics Slides: Corporate presentation

Feb 26, 2026, 7:00 AM EST - 3 months ago

Fate Therapeutics Slides: Corporate presentation

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Feb 16, 2026, 1:00 PM EST - 3 months ago

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

IPSC

Fate Therapeutics presents updated Phase 1 data of FT819

2025-12-08T13:21:05.000Z - 5 months ago

Fate Therapeutics presents updated Phase 1 data of FT819

Fate Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 9:00 AM EST - 6 months ago

Fate Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 6 months ago

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Fate Therapeutics reports Q3 EPS (27c), consensus (28c)

2025-11-13T13:35:50.000Z - 6 months ago

Fate Therapeutics reports Q3 EPS (27c), consensus (28c)

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 13, 2025, 8:30 AM EST - 6 months ago

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 8:30 AM EST - 6 months ago

Fate Therapeutics Earnings release: Q3 2025

Fate Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:30 AM EST - 6 months ago

Fate Therapeutics Quarterly report: Q3 2025

Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

2025-10-31T10:15:39.000Z - 7 months ago

Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7

2025-10-27T13:45:07.000Z - 7 months ago

Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7

Fate Therapeutics upgraded to Outperform from Neutral at Wedbush

2025-10-27T11:05:46.000Z - 7 months ago

Fate Therapeutics upgraded to Outperform from Neutral at Wedbush

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Oct 26, 2025, 11:30 AM EDT - 7 months ago

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Fate Therapeutics appoints Adawi as CFO

2025-10-14T12:15:56.000Z - 7 months ago

Fate Therapeutics appoints Adawi as CFO

Fate Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 10:55 AM EDT - 9 months ago

Fate Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo

2025-08-13T10:20:32.000Z - 10 months ago

Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo

Fate Therapeutics reports Q2 EPS (29c), consensus (34c)

2025-08-12T20:17:43.000Z - 10 months ago

Fate Therapeutics reports Q2 EPS (29c), consensus (34c)

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Aug 12, 2025, 4:01 PM EDT - 10 months ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 10 months ago

Fate Therapeutics Earnings release: Q2 2025

Fate Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 10 months ago

Fate Therapeutics Quarterly report: Q2 2025

Fate Therapeutics announces updated data for FT819

2025-06-11T13:10:38.000Z - 1 year ago

Fate Therapeutics announces updated data for FT819

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 30, 2025, 4:30 PM EDT - 1 year ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 28, 2025, 5:54 PM EDT - 1 year ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

Fate Therapeutics price target lowered to $4 from $5 at Baird

2025-05-14T11:19:42.000Z - 1 year ago

Fate Therapeutics price target lowered to $4 from $5 at Baird

Fate Therapeutics price target lowered to $2 from $10 at Barclays

2025-05-14T09:51:28.000Z - 1 year ago

Fate Therapeutics price target lowered to $2 from $10 at Barclays

Fate Therapeutics reports Q1 EPS (32c), consensus (38c)

2025-05-13T20:10:50.000Z - 1 year ago

Fate Therapeutics reports Q1 EPS (32c), consensus (38c)

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 13, 2025, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Fate Therapeutics Quarterly report: Q1 2025

Fate Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Fate Therapeutics Earnings release: Q1 2025

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Apr 29, 2025, 9:25 AM EDT - 1 year ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Fate Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Proxy statement: Proxy Filing

Fate Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Proxy statement: Proxy Filing

Fate Therapeutics receives RMAT designation from FDA for FT819

2025-04-14T12:06:50.000Z - 1 year ago

Fate Therapeutics receives RMAT designation from FDA for FT819

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Fate Therapeutics Proxy statement: Proxy Filing

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Proxy statement: Proxy Filing

Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 12, 2025, 11:20 AM EDT - 1 year ago

Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Fate Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Fate Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Fate Therapeutics price target lowered to $2.50 from $3 at BofA

2025-03-10T13:27:08.000Z - 1 year ago

Fate Therapeutics price target lowered to $2.50 from $3 at BofA

Fate Therapeutics price target lowered to $3 from $5 at Stifel

2025-03-06T11:55:50.000Z - 1 year ago

Fate Therapeutics price target lowered to $3 from $5 at Stifel

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 5, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Fate Therapeutics Annual report: Q4 2024

Mar 5, 2025, 4:00 PM EST - 1 year ago

Fate Therapeutics Annual report: Q4 2024

Fate Therapeutics Earnings release: Q4 2024

Mar 5, 2025, 4:00 PM EST - 1 year ago

Fate Therapeutics Earnings release: Q4 2024

Fate Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:50 AM EST - 1 year ago

Fate Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 14, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Fate Therapeutics Slides: Corporate Presentation

Feb 7, 2025, 7:00 AM EST - 1 year ago

Fate Therapeutics Slides: Corporate Presentation

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Dec 9, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Fate Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 3:00 PM EST - 1 year ago

Fate Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Fate Therapeutics Transcript: Citi's 2024 Global Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

Fate Therapeutics Transcript: Citi's 2024 Global Healthcare Conference

Fate Therapeutics Announces Leadership Transition

Nov 29, 2024, 1:05 PM EST - 1 year ago

Fate Therapeutics Announces Leadership Transition

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 18, 2024, 8:05 AM EST - 1 year ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 12, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 3:00 PM EST - 1 year ago

Fate Therapeutics Quarterly report: Q3 2024

Fate Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 3:00 PM EST - 1 year ago

Fate Therapeutics Earnings release: Q3 2024

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 9, 2024, 1:30 PM EST - 1 year ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Fate Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2024, 12:45 PM EDT - 1 year ago

Fate Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 1 year ago

Fate Therapeutics Quarterly report: Q2 2024

Fate Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 1 year ago

Fate Therapeutics Earnings release: Q2 2024

Fate Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 3:00 PM EDT - 2 years ago

Fate Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 29, 2024, 4:01 PM EDT - 2 years ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

Fate Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Fate Therapeutics Earnings Call Transcript: Q1 2024

Fate Therapeutics Quarterly report: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Fate Therapeutics Quarterly report: Q1 2024

Fate Therapeutics Earnings release: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Fate Therapeutics Earnings release: Q1 2024

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 9, 2024, 8:30 AM EDT - 2 years ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

May 3, 2024, 4:30 PM EDT - 2 years ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Fate Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Fate Therapeutics Proxy statement: Proxy Filing

Fate Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Fate Therapeutics Proxy statement: Proxy Filing

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 2 years ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Fate Therapeutics Registration statement: Registration Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Fate Therapeutics Registration statement: Registration Filing

Fate Therapeutics Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Fate Therapeutics Proxy statement: Proxy Filing

Fate Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 10, 2024, 2:15 PM EDT - 2 years ago

Fate Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Fate Therapeutics Transcript: H.C. Wainwright 2ND Annual Cell Therapy Virtual Conference

Mar 26, 2024, 3:00 PM EDT - 2 years ago

Fate Therapeutics Transcript: H.C. Wainwright 2ND Annual Cell Therapy Virtual Conference

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 19, 2024, 8:44 AM EDT - 2 years ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Fate Therapeutics Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 12, 2024, 11:15 AM EDT - 2 years ago

Fate Therapeutics Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Fate Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 11, 2024, 2:00 PM EDT - 2 years ago

Fate Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Fate Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 6, 2024, 9:10 AM EST - 2 years ago

Fate Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Fate Therapeutics to Present at Upcoming March Investor Conferences

Mar 1, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Fate Therapeutics Earnings Call Transcript: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Fate Therapeutics Earnings Call Transcript: Q4 2023

Fate Therapeutics Annual report: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Fate Therapeutics Annual report: Q4 2023

Fate Therapeutics Earnings release: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Fate Therapeutics Earnings release: Q4 2023

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 26, 2024, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 13, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Slides: Corporate Presentation

Nov 9, 2023, 8:00 PM EST - 2 years ago

Fate Therapeutics Slides: Corporate Presentation

Fate Therapeutics Earnings Call Transcript: Q3 2023

Nov 8, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Earnings Call Transcript: Q3 2023

Fate Therapeutics Quarterly report: Q3 2023

Nov 8, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Quarterly report: Q3 2023

Fate Therapeutics Earnings release: Q3 2023

Nov 8, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Earnings release: Q3 2023

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Nov 8, 2023, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Fate Therapeutics Registration statement: Registration Filing

Nov 8, 2023, 7:00 AM EST - 2 years ago

Fate Therapeutics Registration statement: Registration Filing

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Fate Therapeutics Transcript: Wells Fargo Securities Healthcare Conference 2023

Sep 8, 2023, 9:30 AM EDT - 2 years ago

Fate Therapeutics Transcript: Wells Fargo Securities Healthcare Conference 2023

Fate Therapeutics to Present at Upcoming September Investor Conferences

Aug 31, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Present at Upcoming September Investor Conferences

Fate Therapeutics Earnings Call Transcript: Q2 2023

Aug 8, 2023, 5:00 PM EDT - 3 years ago

Fate Therapeutics Earnings Call Transcript: Q2 2023

Fate Therapeutics Quarterly report: Q2 2023

Aug 8, 2023, 5:00 PM EDT - 3 years ago

Fate Therapeutics Quarterly report: Q2 2023

Fate Therapeutics Earnings release: Q2 2023

Aug 8, 2023, 5:00 PM EDT - 3 years ago

Fate Therapeutics Earnings release: Q2 2023

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Aug 8, 2023, 4:01 PM EDT - 3 years ago

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

Jul 28, 2023, 8:00 AM EDT - 3 years ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

Fate Therapeutics Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

Jun 13, 2023, 5:00 PM EDT - 3 years ago

Fate Therapeutics Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

Fate Therapeutics to Present at Upcoming June Investor Conferences

May 31, 2023, 8:00 AM EDT - 3 years ago

Fate Therapeutics to Present at Upcoming June Investor Conferences

WestEgg
WestEgg May. 21 at 3:03 PM
$FATE Scenario Approximate Enterprise Value Technology tuck-in $1B–$2B Strong autoimmune validation $3B–$5B Breakthrough outpatient CAR-T platform $5B–$10B+
0 · Reply
WestEgg
WestEgg May. 21 at 2:34 PM
$FATE Most Likely Order $1B-$7B 1. Bristol Myers Squibb 2. Gilead/Kite 3. AstraZeneca 4. Johnson & Johnson 5. Novartis 6. Regeneron 7. Roche The single biggest determinant now is whether FT819’s autoimmune data continues improving through 2026.
0 · Reply
Rocketman808
Rocketman808 May. 21 at 2:18 PM
$FATE 2000 more shares at 1.80 was all i could do but glad i acted quick!! lets hit 2s again!!
0 · Reply
student56
student56 May. 21 at 2:14 PM
$FATE hold
0 · Reply
Icansee
Icansee May. 21 at 1:45 PM
$FATE
0 · Reply
Rocketman808
Rocketman808 May. 21 at 1:39 PM
$FATE nice place to add waiting for payday lol
0 · Reply
Doozio
Doozio May. 20 at 11:57 PM
The $FATE of da YO vs turnaround Tuesday $HALO ONTO 🐒🍌🧠⏰♾️
0 · Reply
GoosingIt
GoosingIt May. 20 at 10:18 PM
$FATE Will be interested to see if a positive FT836 abstract moves this tomorrow.
0 · Reply
buymoremakemore
buymoremakemore May. 20 at 3:36 PM
$FATE I added 32k shares here. It was between this and IPSC. Pipeline and cash look good here. Could be takeout target
0 · Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates May. 20 at 2:18 PM
$FATE "The firm also expects strong responses and durability comparable to autologous CAR-T therapy" - Excerpt from the following article: https://www.investing.com/news/analyst-ratings/jefferies-initiates-fate-therapeutics-stock-with-buy-rating-on-autoimmune-potential-93CH-4699446
0 · Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates May. 20 at 2:16 PM
$FATE "Jefferies said it will look for favorable safety data including no immune effector cell-associated neurotoxicity syndrome and low-grade cytokine release syndrome. The firm also expects strong responses and durability comparable to autologous CAR-T therapy" https://www.investing.com/news/analyst-ratings/jefferies-initiates-fate-therapeutics-stock-with-buy-rating-on-autoimmune-potential-93CH-4699446
0 · Reply
Rocketman808
Rocketman808 May. 20 at 1:47 PM
$FATE how is sentiment bearish here 😂🚀
0 · Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates May. 20 at 12:13 PM
$FATE
0 · Reply
student56
student56 May. 20 at 7:39 AM
$FATE something happening here
1 · Reply
David_M_
David_M_ May. 20 at 2:18 AM
$FATE soon...
0 · Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates May. 20 at 12:54 AM
$FATE https://www.investing.com/news/analyst-ratings/jefferies-initiates-fate-therapeutics-stock-with-buy-rating-on-autoimmune-potential-93CH-4699446
0 · Reply
notreload_ai
notreload_ai May. 19 at 7:47 PM
Jefferies has initiated coverage of $FATE stock with a “Buy” rating and a $4 price target. Its lead drug, FT819, is in early-stage testing for autoimmune diseases and could provide a convenient, on-demand outpatient treatment for severe cases of lupus affecting the kidneys or other organs.
0 · Reply
Rocketman808
Rocketman808 May. 19 at 7:17 PM
$FATE i like buyouts
1 · Reply
wenmoon_stonks
wenmoon_stonks May. 19 at 5:56 PM
$FATE interesting
0 · Reply
WestEgg
WestEgg May. 19 at 5:50 PM
$FATE they brought the stock down to shake out retail- Praying for a deal over $1B!
1 · Reply
Rocketman808
Rocketman808 May. 19 at 5:23 PM
$FATE i went all in
3 · Reply
WestEgg
WestEgg May. 19 at 5:22 PM
$FATE maybe they have a deal done at the HC Conference
0 · Reply